Two Sigma Advisers LP Has $6.50 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Two Sigma Advisers LP boosted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,900 shares of the company's stock after purchasing an additional 6,200 shares during the quarter. Two Sigma Advisers LP's holdings in Zoetis were worth $6,501,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares during the period. Geode Capital Management LLC lifted its holdings in Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC boosted its stake in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Wellington Management Group LLP boosted its stake in Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the period. Finally, Northern Trust Corp grew its holdings in Zoetis by 13.3% in the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after buying an additional 755,893 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus reduced their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Finally, UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $212.75.

Zoetis Price Performance

Shares of ZTS stock traded down $1.06 during trading hours on Wednesday, reaching $165.20. The company's stock had a trading volume of 1,691,156 shares, compared to its average volume of 2,524,548. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm's 50 day simple moving average is $156.53 and its 200-day simple moving average is $164.69. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $73.55 billion, a price-to-earnings ratio of 30.20, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.38 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.